21 research outputs found

    TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.

    Get PDF
    Hypoxia and interactions with bone marrow (BM) stromal cells have emerged as essential components of the leukemic BM microenvironment in promoting leukemia cell survival and chemoresistance. High levels of transforming growth factor beta 1 (TGFβ1) produced by BM stromal cells in the BM niche regulate cell proliferation, survival, and apoptosis, depending on the cellular context. Exogenous TGFβ1 induced accumulation of acute myeloid leukemia (AML) cells in a quiescent G0 state, which was further facilitated by the co-culture with BM-derived mesenchymal stem cells (MSCs). In turn, TGFβ-neutralizing antibody 1D11 abrogated rhTGFβ1 induced cell cycle arrest. Blocking TGFβ with 1D11 further enhanced cytarabine (Ara-C)-induced apoptosis of AML cells in hypoxic and in normoxic conditions. Additional constituents of BM niche, the stroma-secreted chemokine CXCL12 and its receptor CXCR4 play crucial roles in cell migration and stroma/leukemia cell interactions. Treatment with 1D11 combined with CXCR4 antagonist plerixafor and Ara-C decreased leukemia burden and prolonged survival in an in vivo leukemia model. These results indicate that blockade of TGFβ by 1D11 and abrogation of CXCL12/CXCR4 signaling may enhance the efficacy of chemotherapy against AML cells in the hypoxic BM microenvironment

    Plerixafor and 1D11 inhibit CXCL12-induced migration.

    No full text
    <p>Chemotaxis assay of MV4;11 cells treated with TGF-β1 (2 ng/ml), 1D11 (10 µM), and/or plerixafor (1 µM) for 18 hours. Cells were stimulated with CXCL12 (100 ng/mL) for 4 hours. In all experiments, the chemotactic index was calculated as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062785#s2" target="_blank">Materials and Methods</a>. Graphs show the means ± SD of the results from three independent experiments. *<i>P</i><0.05, **<i>P</i><0.01.</p

    TGF-β-neutralizing antibody1D11 suppresses TGF-β signaling in AML cells.

    No full text
    <p>(A) Percentage of MV4;11, U937 and THP-1 cells showing annexin V positivity after 72 hours of treatment with or without rhTGF-β1 (2 ng/ml) and the indicated concentrations of Ara-C. Graphs show the means ± SD of the results from three independent experiments. (B)(C) MV4;11 and U937 cells were treated with TGF-β1 (2 ng/ml), 1D11 (10 µM), or 13C4 (10 µM) for 24 hours. (B) Expression of phospho (p-) Smad2 and p21 proteins by western blot analysis. Clarified lysates were probed with antibodies to p-Smad2, p21 and α-tubulin. Results shown are representative of three independent experiments. (C) <i>PAI-1</i> (plasminogen activator inhibitor-1) mRNA expression detected by TaqMan RT-PCR analysis. The abundance of transcripts of <i>PAI-1</i> relative to the abundance of transcripts of <i>GAPDH</i> was determined as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0062785#s2" target="_blank">Materials and Methods</a>. Results shown are representative of three experiments. *<i>P</i><0.05, ** <i>P</i><0.01.</p
    corecore